Oncology

Bladder cancer

  • Burden of disease deck in bladder cancer
  • Payer value deck in bladder cancer
  • Frequently asked questions in bladder cancer
  • Payer implementation guide in bladder cancer
  • Burden of disease deck, payer value dossier deck and frequently asked questions deck in 2nd line bladder cancer
  • Burden of disease deck in non-muscle invasive bladder cancer
  • Payer value deck update in 2nd line bladder cancer
  • Standardization of economic models in bladder cancer
  • Qualitative research in bladder cancer
  • Clinical trial analyses to support health-related quality of life in bladder cancer
  • ‘Fit for purpose’ tools review in bladder cancer
  • Development of a new PRO measure in bladder cancer
  • AMNOG analyses to support health-related quality of life in bladder cancer

Brain metastases

  • Development and validation of a PRO measure in brain metastases
  • Development and validation of a questionnaire to assess brain metastases
  • Linguistic validation of a brain metastases assessment

Brain tumours

  • Health Economics and Translational Advisory Board on paediatric brain tumours
  • Support in personalised medicine health economics on brain tumours

Breast cancer

  • Global value dossier for treatment in breast cancer
  • Data collection of costs associated with breast cancer care
  • Manuscript on the German model for a hormonal drug used in the treatment of breast cancer
  • Development of two budget impact models in breast cancer with population data by city
  • Two budget impact models for Italy for an injectable chemotherapy drug for breast cancer
  • Budget impact model in breast cancer for France
  • Development of a cost-calculator for a biosimilar for breast cancer
  • Payer value deck in breast cancer
  • Payer value deck update for a breast cancer biosimilar
  • Burden of disease deck in breast cancer
  • Response to payer questions in breast cancer
  • Response to payer questions update for a breast cancer biosimilar
  • Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
  • One-pager communication in a breast cancer biosimilar
  • Productivity and QoL study in breast cancer
  • Literature review and consultancy on breast cancer
  • e-v@luate platforms in breast cancer

HER2 positive breast cancer

  • Literature review of productivity data in HER2 positive breast cancer
  • Budget impact model for a biosimilar in HER2 breast cancer

Advanced breast cancer

  • Development of a perceived tolerability questionnaire in first line treatment of advanced breast cancer
  • Strategy for an injectable chemotherapy drug for advanced breast cancer and submission to NICE/SMC
  • Budget impact model and analysis for an injectable chemotherapy drug for advanced breast cancer in 5 EU countries
  • Economic evaluation of a therapy for postmenopausal women with advanced breast cancer (with the perspective of 3rd party national and local payers in the UK)
  • Development and population of an economic model in advanced breast cancer
  • Conference poster on a cost utility analysis of two treatments for advanced breast cancer
  • Conference poster on the economic evaluation of a therapy for postmenopausal women with advanced breast cancer
  • Phase IV non-interventional prospective observational study comparing patient reported outcomes in advanced breast cancer
  • PRO label review manuscript development in advanced/metastatic breast cancer

Metastatic breast cancer

  • Value dossier and e-v@luate platform in metastatic breast cancer
  • Scientific communication of cost-effectiveness analysis in metastatic breast cancer
  • PRO knowledge base instruments and methods library for metastatic breast cancer

Triple negative breast cancer

  • Global value dossier and upload to e-v@luate platform in triple negative breast cancer
  • Data analyses on a multi-indication budget impact model and cost utility model in triple negative breast cancer
  • Standalone budget impact models in triple negative breast cancer

Cancer-related pain, fatigue and side effects

Cancer-related pain and fatigue

  • Initial consultation to design a study in order to generate health utilities values associated with different levels of cancer-related pain
  • Utility study in breakthrough cancer pain
  • Update of report for utility elicitation in breakthrough cancer pain
  • Abstract, manuscript and budget impact model on breakthrough cancer pain
  • Training in pilot budget impact model for a treatment for patients with breakthrough cancer pain
  • SMC submission in breakthrough cancer pain
  • Development of a breakthrough cancer pain submission to the All Wales Medicines Strategy Group (AWMSG)
  • Attendance at an AWMSG meeting with regards to strategic consultancy in breakthrough cancer pain
  • Expert interviews and amendment project to heath economic model for a treatment for breakthrough cancer pain
  • Economic evaluation of a treatment for breakthrough cancer pain in Canada
  • Budget impact tool for a treatment for patients with breakthrough cancer pain in the UK
  • Consulting support and development of a briefing document to support fatigue symptom claims in cancer pain
  • Recommendation of a measure of chronic cancer pain
  • Assessment of a pain communication tool for advanced cancer patients: a cross-sectional survey
  • Qualitative research for the Cancer-Related Fatigue Consortium
  • Phase II cognitive interviews on Patient-Reported Outcomes of Fatigue – Cancer (PROOF-C)
  • Cancer-related fatigue consortium: qualitative research in the experience of fatigue among cancer patients
  • Qualitative research on the experience of fatigue among cancer patients
  • PRO development, abstracts and posters on cancer-related fatigue

Cancer-related anaemia

  • Linking a cost utility assessment model with a budget impact model for treatment for anaemia in cancer
  • NICE consultancy for a treatment for chemotherapy-induced anaemia
  • Statistical pharmacoeconomic analysis of patient level data for a treatment for anaemia following chemotherapy
  • Phase II cognitive interviews and regulatory support in inflammatory anaemia in cancer
  • Evaluation of the PRO landscape using a systematic literature review on chemo-induced anaemia in oncology

Other cancer-related side effects

  • Value dossier on a drug used to treat febrile neutropenia
  • Plan, execute and follow up a Train-the-Trainer meeting on chemotherapy-induced febrile neutropenia
  • Development of a PRO measure in muscle wasting (cancer cachexia) in prostate cancer, sarcopenia, gastric cancer and colorectal cancer
  • Debriefing of the cancer associated fibroblasts (CaF) PRO
  • SMC re-submission and economic analysis for a treatment for anthracycline extravasation
  • Case control study of costs associated with a treatment for oral mucositis in transplant patients
  • Literature review and recommendations on PROs for peripheral neuropathy due to chemotherapy in cancer patients
  • Review of PRO instruments for use in uveal melanoma and biliary tract cancer

Cervical cancer

  • Development of a PRO strategy in cervical cancer and HPV
  • Summary report, top-up literature review, meta-analysis, editorial board and manuscripts on HPV infection and cervical cancer

Colorectal cancer

  • Project management of a mixed treatment analysis on colorectal cancer
  • Update to a payer value slide deck in metastatic colorectal cancer
  • Value-based model in colorectal cancer
  • Payer communications strategy and tools in colorectal cancer
  • Reimbursement dossiers in subgroups of colorectal cancer
  • Mini literature review in metastatic colorectal cancer
  • Literature review and payer communication tools in metastatic colorectal cancer
  • Translation to support development of a value dossier and budget impact model in capsule endoscopy for colonoscopy
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on colorectal cancer
  • PRO assessment on the neurotoxicity of a treatment for advanced colorectal cancer
  • Clinical trial analyses to support HRQoL in recurrent and metastatic microsatellite instability high colorectal cancer
  • White Paper on continuous infusion in colorectal cancer
  • Development of cost arguments and brochure development in colorectal cancer
  • Network meta-analysis on the efficacy of treatment for metastatic colorectal cancer
  • Recommendations on the economic impact of a treatment for metastatic colorectal cancer
  • Network meta-analysis of a treatment versus other biologics for metastatic colorectal cancer in 1st line, 2nd line and multiple line settings
  • Web-based survey to understand patient-preference and satisfaction in advanced colorectal cancer

Esophogeal cancer

  • Payer value deck in esophogeal cancer
  • Burden of disease deck in esophogeal cancer
  • Response to payer questions in esophogeal cancer
  • Clinical trial analyses to support HRQoL in oesophageal cancer

Gastric cancer

  • Global value dossier for treatment in gastric cancer
  • Development of a cost-calculator for a biosimilar for gastric cancer
  • Review of a SMC submission for a chemotherapy drug for advanced gastric cancer
  • Burden of disease deck, payer value dossier deck and frequently asked questions deck in gastric cancer
  • Payer value deck in 1st line gastric cancer
  • Response to payer questions in 1st line gastric cancer
  • Literature and PRO strategy for gastric oesophageal cancer
  • Literature review and development of a PRO strategy for gastric cancer
  • Statistical analyses to support HRQoL in gastric cancer, and estimation of EQ-5D utilities for an Asian population in a trial based on existing data and non-Asian trial utility data
  • Advisory board attendance and presentation for utilities in gastric cancer and illustrative summary analyses
  • Utilities analyses to support economic modelling in gastric cancer

Glioblastoma

  • Development of a global value dossier in the treatment of glioblastoma
  • AMCP dossier in glioblastoma multiforme
  • Early global value dossier in newly diagnosed glioblastoma
  • Clinical trial analyses to support health-related quality of life (HRQoL) in glioblastoma
  • Review of instruments for a glioblastoma trial and recommendation of a strategy
  • PRO dossier on glioblastomas for the EMA
  • Literature review on overall survival and progression-free survival in glioblastomas
  • Poster on the association of HRQoL and NCF with progression-free survival (PFS) and PD in glioblastoma
  • Indirect comparison of two treatments in 2nd line glioblastoma
  • Training slide deck for COAs in glioblastoma